Editas Medicine (NASDAQ: EDIT) director granted 51,700 stock options at $2.55

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Editas Medicine director Jessica Hopfield received a new stock option grant. On June 17, 2026, she was awarded options to acquire 51,700 shares of Editas Medicine common stock at an exercise price of $2.55 per share.

The option is scheduled to vest in full on June 17, 2027 and will expire on June 16, 2036 if not exercised. Following this grant, she holds options covering 51,700 shares directly as reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hopfield Jessica

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	51,700	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 51,700 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 51,700 shares Exercise price: $2.55 per share Post-grant option holdings: 51,700 shares +2 more

5 metrics

Option grant size 51,700 shares Stock options to buy common stock granted June 17, 2026

Exercise price $2.55 per share Conversion or exercise price of the stock options

Post-grant option holdings 51,700 shares Total shares underlying options following the transaction

Vesting date June 17, 2027 Options scheduled to vest in full on this date

Expiration date June 16, 2036 Options expire if not exercised by this date

Key Terms

Stock Option (right to buy), exercise price, vesting, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "2.5500" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"scheduled to vest in full on June 17, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-06-16T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/22/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopfield Jessica

(Last)

(First)

(Middle)

C/O EDITAS MEDICINE, INC.,

11 HURLEY ST.

(Street)

CAMBRIDGE

MASSACHUSETTS

02141

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.55	06/17/2026		A		51,700		⁽¹⁾	06/16/2036	Common Stock	51,700	$0	51,700	D

Explanation of Responses:

1. This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.

Remarks:

	/s/ Jessica Hopfield	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Editas Medicine (EDIT) director Jessica Hopfield report in this Form 4?

Jessica Hopfield reported receiving a stock option grant for 51,700 shares of Editas Medicine common stock. The award is a compensation-related grant, not an open-market purchase or sale, and represents options rather than currently outstanding common shares.

What are the key terms of Jessica Hopfield’s new Editas Medicine (EDIT) stock options?

The grant covers options to buy 51,700 Editas Medicine common shares at an exercise price of $2.55 per share. These options are scheduled to vest in full on June 17, 2027 and expire on June 16, 2036 if not exercised.

Is Jessica Hopfield buying or selling Editas Medicine (EDIT) stock in this Form 4?

She is not buying or selling shares on the open market. The Form 4 shows a grant of stock options as compensation, coded as an acquisition (A), giving her the right to buy 51,700 shares at a fixed $2.55 exercise price.

How many Editas Medicine (EDIT) shares are covered by Jessica Hopfield’s options after this grant?

After this grant, Jessica Hopfield holds options covering 51,700 shares of Editas Medicine common stock directly. These options represent potential future share ownership if exercised, rather than currently issued or outstanding common shares.

When do Jessica Hopfield’s Editas Medicine (EDIT) stock options vest and expire?

The options are scheduled to vest in full on June 17, 2027, meaning they become exercisable on that date. They carry an expiration date of June 16, 2036, after which any unexercised options will lapse.